- Home
- GTN vs TBPH Comparison
GTN vs TBPH Comparison
Compare GTN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTN
- TBPH
- Stock Information
- Founded
- GTN 1897
- TBPH 2013
- Country
- GTN United States
- TBPH United States
- Employees
- GTN N/A
- TBPH N/A
- Industry
- GTN Broadcasting
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- GTN Industrials
- TBPH Health Care
- Exchange
- GTN Nasdaq
- TBPH Nasdaq
- Market Cap
- GTN 617.6M
- TBPH 699.0M
- IPO Year
- GTN N/A
- TBPH N/A
- Fundamental
- Price
- GTN $5.86
- TBPH $14.30
- Analyst Decision
- GTN Strong Buy
- TBPH Strong Buy
- Analyst Count
- GTN 4
- TBPH 4
- Target Price
- GTN $6.88
- TBPH $23.00
- AVG Volume (30 Days)
- GTN 1.2M
- TBPH 568.6K
- Earning Date
- GTN 11-07-2025
- TBPH 11-11-2025
- Dividend Yield
- GTN 5.46%
- TBPH N/A
- EPS Growth
- GTN 1482.23
- TBPH N/A
- EPS
- GTN 1.53
- TBPH 0.26
- Revenue
- GTN $3,549,000,000.00
- TBPH $77,205,000.00
- Revenue This Year
- GTN N/A
- TBPH $79.82
- Revenue Next Year
- GTN $13.37
- TBPH N/A
- P/E Ratio
- GTN $3.83
- TBPH $55.89
- Revenue Growth
- GTN 7.03
- TBPH 24.49
- 52 Week Low
- GTN $2.91
- TBPH $7.88
- 52 Week High
- GTN $6.31
- TBPH $14.55
- Technical
- Relative Strength Index (RSI)
- GTN 53.36
- TBPH 71.65
- Support Level
- GTN $5.57
- TBPH $13.47
- Resistance Level
- GTN $6.29
- TBPH $14.36
- Average True Range (ATR)
- GTN 0.25
- TBPH 0.42
- MACD
- GTN -0.07
- TBPH -0.07
- Stochastic Oscillator
- GTN 38.51
- TBPH 76.85
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).